Free Trial

Jazz Pharmaceuticals (JAZZ) Earnings Date, Estimates & Call Transcripts

Jazz Pharmaceuticals logo
$110.45
+0.42 (+0.38%)
(As of 11/1/2024 ET)

Jazz Pharmaceuticals Latest Earnings Summary

Upcoming Q3
Earnings Date
Nov. 6After Market ClosesConfirmed
Actual EPS
(Jul. 31)
$4.67 Beat By $0.87
Consensus EPS
(Jul. 31)
$3.80

Jazz Pharmaceuticals issued Q2 2024 earnings on July 31, 2024, reporting an EPS of $4.67, which beat analysts' consensus estimates of $3.80 by $0.87. Quarterly revenue was reported to be $1.02 billion, above analyst estimates of $1 billion. With a trailing EPS of $5.82 and a P/E Ratio of 18.98, Jazz Pharmaceuticals' earnings are expected to grow 16.35% next year, from $16.02 to $18.64 per share.

JAZZ Upcoming Earnings

Jazz Pharmaceuticals' next earnings date is scheduled for Wednesday, November 6, 2024, with a conference call scheduled for at 4:30 PM ET. Interested parties can register for or listen to the call.


Skip Charts & View Estimated and Actual Earnings Data

JAZZ Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

JAZZ Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Jazz Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20242$3.24$3.60$3.42 
Q2 20242$3.68$4.23$3.96 
Q3 20242$4.34$4.52$4.43 
Q4 20241$4.83$4.83$4.83 
FY 20247$16.09$17.18$16.64 
Q1 20251$3.13$3.13$3.13 
Q2 20251$4.09$4.09$4.09 
Q3 20251$4.35$4.35$4.35 
Q4 20251$4.55$4.55$4.55 
FY 20254$16.12$16.12$16.12 
Q1 20261$3.77$3.77$3.77 
Q2 20261$4.33$4.33$4.33 
Q3 20261$4.67$4.67$4.67 

Jazz Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
11/6/2024
(Confirmed)
-------  
7/31/2024Q2 2024$3.80$4.67+$0.87$6.85$1.00B$1.02B
5/1/2024Q1 2024$3.53$1.98 -$1.55$4.19$938.99M$901.98M    
2/28/2024Q4 2023$4.44$4.40 -$0.04$7.38$1.01B$1.01B        
11/8/2023Q3 2023$4.21$4.22+$0.01$6.30$969.47M$972.14M    
8/9/2023Q2 2023$3.68$3.83+$0.15$6.14$952.44M$957.32M    
5/10/2023Q1 2023$3.58$3.20 -$0.38$5.36$898.11M$892.81M    
2024 Election Year Stocks: Uncover Hidden Gems! (Ad)

In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss.

Secure your copy now by clicking this link.
3/1/2023Q4 2022--$0.84 -$0.84$2.14$972.70M$972.12M    
11/9/2022Q3 2022$4.35$4.53+$0.18$9.37$939.88M$940.65M    

Jazz Pharmaceuticals Earnings - Frequently Asked Questions

Jazz Pharmaceuticals has confirmed that its next quarterly earnings data will be published on Wednesday, November 6th, 2024. Learn more on JAZZ's earnings history.

In the previous quarter, Jazz Pharmaceuticals (NASDAQ:JAZZ) reported $4.67 earnings per share (EPS) to beat the analysts' consensus estimate of $3.80 by $0.87. Learn more on analysts' earnings estimate vs. JAZZ's actual earnings.

Jazz Pharmaceuticals (NASDAQ:JAZZ) has a recorded annual revenue of $3.83 billion.

Jazz Pharmaceuticals (NASDAQ:JAZZ) has a recorded net income of $414.83 million. JAZZ has generated $5.82 earnings per share over the last four quarters.

Jazz Pharmaceuticals (NASDAQ:JAZZ) has a trailing price-to-earnings ratio of 18.98 and a forward price-to-earnings ratio of 6.89. The price/earnings-to-growth ratio is 1.42.

Jazz Pharmaceuticals's earnings are expected to grow from $16.02 per share to $18.64 per share in the next year, which is a 16.35% increase.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:JAZZ) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners